| Galvanotherapy Percutaneous Bio-Electrotherapy for the Elimination of
Malignant Tumors Townsend Letter for Doctors and Patients, Nov, 2001 by Morton Walker << Page 1 Continued from page 1. Previous | Next History of Pekar's Percutaneous Bio-Electrotherapy Invention Dr. med. Rudolph Pekar, born in 1912, studied at the Vienna School of Medicine. Shortly after the end of World War II, he began his private medical practice in Bad Ischl, Austria in 1946. He first began to treat tumors with galvanic applications in 1969 and compiled a description of his clinical experiences for publication in 1988. It was with his publishing of that first monograph that he first called his treatment invention, galvanotherapy. The name has stuck despite his formally renaming the treatment Percutaneous Rio-Electrotherapy. Dr. med. Rudolph Pekar self-published another fuller disclosure of his work against cancerous tumors using GT or PBE, in a second monograph during the latter part of 1997. It is an elegant little book translated from German to English. In April and May of 1999 when I began investigating German cancer therapies from my base of operations at Klinik Winnerhof in bad Wiessee, Bavaria, Germany, Dr. med. Pekar contacted me through my friend and cancer consultant Helmut Keller, MD, and asked that I, as a medical journalist who specializes in writing on complementary and alternative medicine (CAM), provide broader exposure for his cancer treatment. The doctor desires to allow more patients access to the benefits of his therapy's efficacy for cancer. He believed that galvanotherapy or bio-electrotherapy was too little known outside of German-speaking medical circles, and he was correct. Advertisement Today, at age 90, this inventor of galvanotherapy wants to leave behind a legacy of healing. Consequently, he has given me written permission to quote freely from his 1997 monograph, and I have done so. Here is my interpretation of the monograph Percutaneous Bio-Electrotherapy of Cancerous Tumours by the treatment's inventor, Dr. med. Rudolph Pekar. [1] The Physiological Mechanism of Anti-Cancer Galvanotherapy With great success, the Pekar treatment has already been administered to an estimated 65,000 patients throughout Europe and a few other parts of the world. The bioelectrotherapy (BET) used for galvanotherapy has advantages over surgical intervention. BET does not provoke metastasis. It does not stress the cancer patient. Frequently, its nonanesthetized application hurts in the form of a stinging electric current. But this stinging or burning sensation may be controlled effectively by the patient's first receiving local injections of lidocaine, xylocaine, or another dental-type anesthetic at the administration site of GT. Negatively charged particles called anions migrate to the positively
charged pole, an anode, in the electrochemical cell. Positively charged
particles called cations migrate to the negatively charged pole, a cathode.
Between the poles, a charge separation or dissociation occurs. This dissociation
damages malignant tissue in the following manner: extremely acidic tissue
plus chlorine is generated at the anode; conversely, a markedly alkaline
environment plus hydrogen is generated at the cathode. According to their
charge, small and large ionic particles such as those in proteins, separate
inside of the electrical field. The cancer cells caught between this
electrochemical reaction completely depolarize, so that they become permeable
and accepting of various substances poisonous to them. Meantime, therapeutic
agents are being administered intravenously to the patient. Thus, the
tumor tissue at the treated site can no longer maintain its specific
equilibrium, and it destabilizes. Types of Tumors Responding to Galvanotherapy Particular tumor types respond well to galvanotherapy. Under the ministrations of Dr. med. Rudolf Pekar and his oncolgical colleagues, this form of electrotherapy is successful for eliminating the following malignant conditions: * Breast cancers * Mouth and throat cancers * Esophageal and stomach cancers * Lung cancers * Vaginal cancers * Melanomas and basal-cell carcinomas * Skin metastases * Lymph node metastases * Liver metastases * Mycosis fungoides * Rectal cancer & anal cancer The use of GT for malignant tumor removal has many advantages. Such benefits consist of the following: a. The organ involved is preserved with no problematic scarring. Advertisement b. The electrical needles are applied under local anesthesia without risks. c. None of the side effects which may be connected with general anesthesia are present. d. No damage occurs to healthy tissue. e. As a result of lysed tumor components being presented to the immune system for removal, an additional immune stimulation takes place. From receiving galvanotherapy, certain types of cancer patients benefit greatly. Such malignancy types include: * those with small primary tumors of less than 5 cm in diameter; * those with solitary metastases, especially in the skin and lymph nodes; * those with recurrences in the region of an operation such as a mastectomy scar; * those who have inoperable external tumors. The Introduction of Rio-Electrotherapy into China In addition to Rudolf Pekar, MD, who administers bioelectrotherapy from his clinic at the Onckologische Schwerpunktpraxis in Bad Ischl, Austria, five other oncologists have participated with him in gathering statistics solely related to their galvanotherapy applications for cancer. The five physicians are: SwenAlfas, MD, Chairman of the Academy for Applied Knowledge International in Frederiksberg, Denmark; Friedrich Douwes, MD, Medical Director of the Klinik St. Georg in Bad Abling, Germany; Giuseppe Gasso, MD, Oncologist-in-Chief at the Centro Catanese di Onkologia in Catania, Italy; Xin Yu-Ling, MD, the Cancer Clinic Director at the China-Japan Friendship Hospital in Beijing, China; Helmut Keller, MD, Former Medical Director of Klinik Winnerhof, Bad Wiessee, Bavaria, Germany. These outstanding oncologists who utilize CAM techniques for reversing cancer are prime exponents of galvanotherapy. From his own practice experience with cancer treatment, Dr. med. Rudolf Pekar says that a 73% rate of remission for not less than three years is what bio-electrotherapy achieves. He does qualify his statement with these words: "It should be noted, though, that in my practice, I have only been able to treat mild and moderate tumours." In 1988, Nobel laureate Professor Bjorn E. W. Nordenstrom, MD, PhD, of Stockholm, Sweden introduced electrochemotherapy, with galvanotherapy as a primary component, to Chinese healers. By 1993, this treatment was already being performed in 818 hospitals throughout China. The Chinese medical community had picked up on galvanotherapy with great vigor in the same way they had readily adapted the porcine splenic extract, Polyerga [R], for their ailing cancer patients. Bio-Electrotherapy intrigued them with its quick-acting electromagnetic fields of healing. The 200-year-old model of biological matter, introduced by Dalton in 1808, is still widely used in the science of medicine within China. This model is based on a highly simplified assumption that matter consists ultimately of indivisible discrete atomic particles. The attraction of atoms to each other leads to a chemical reaction. Binding forces between the atoms are visualized along abstract lines as in the meridians of acupuncture.Besides the chemical reactions between matter, an additional, more profound countereffect has been observed since Dalton introduced his theory. Matter, particularly biological matter, radiates electromagnetic fields at all times. And Dr. med. Rudolf Pekar, even as a young physician, realized this fact. He states in his book: "Every biological process is also an electric process. Health and sickness are related to the bio-electric currents in our body." This conclusion of Pekar's is a new paradigm for understanding biological substance. The therapeutic application of that knowledge and the introduction of electric current into the tumor with needle-electrodes are epoch-making ventures, and the influence of electricity on cancer cells is profound. Those Chinese physicians aware of Dr. med. Pekar's concept have recognized its importance, far in advance of physicians practicing conventional allopathic medicine in North America. Advertisement Healing Statistics for Galvanotherapy Reported Out of China As a result of the First International Conference of Bio-Electrotherapy (BET) for Cancer held in Beijing, China in 1992, a statistical breakdown of the treatment's administration showed the results of applying galvanotherapy for all types of tumors in 2,500 cases. Every one of the cases had been presented to the conference attendees by Chinese medical scientists (see Table 1). Their statistics indicated that for a wide variety of malignant tumors, more than 35% of the cancer patients experienced Complete Remissions (CR). And almost 43% showed Partial Remissions (PR). Over 15% could report No Change (NC); and less than 7% exhibited Progressive Disease (PD). The table below offers a summary of the Chinese medical experience with the use of galvanotherapy (bio-electrotherapy) for malignant tumors. Statistics for the patients' case histories tell the whole story of treatment efficacy. The participating Chinese doctors' experience is undeniable, and their therapeutic responses from cancer patients are extraordinary. There should be absolutely no reason for continuing to deny patients residing in North America access to receiving galvanotherapy for malignancy elimination. The Three-Year Remission Rate for BET or GT At the Second International Conference of Bio-Electrotherapy for Cancer held in Stockholm, Sweden in 1993, the Chinese oncological participants reported that their galvanotherapy administrations to 4,000 cancer patients resulted in an accumulation of Complete Remissions and Partial Remissions (CR + PR) exceeding 80%. This remission rate is better than any other reported therapy for malignancies. It far outshines chemotherapy and radiation therapy as delivered in the United States. The American Cancer Society (ACS) considers chemotherapy to be beneficial at only a 5% response rate. How would the ACS classify galvanotherapy? The answer is that the ACS labels galvanotherapy as "experimental" or "investigational" or "unconventional." The Chinese have given GT legitimacy because the three-year survival rate for Chinese cancer patients receiving galvanotherapy lies well above 70 percent. Similar or even better results than those clinical studies published in China were achieved with galvanotherapy for all types of cancers by Professor Giuseppe Gasso, MD, of Catania, Italy. Worldwide, the estimated average percentage of three-year remissions arising from the application of galvanotherapy is about 72% for most types of tumors and cancer stagings. The Austrian inventor and expert on bio-electrotherapy, Rudolf Pekar, MD, reports the best average three-year remission rate he has experienced is 73%. (Unlike in the United States, European oncologists consider that "near-cure" has been achieved for a cancer patient in the presence of a three-year remission.) Resource To be educated more fully about applying the science and techniques of galvanotherapy/bio-electrotherapy, contact Dr. med. Rudolf Pekar, MD, President of the International Association for Electromedicine at his cancer specialty practice Onkologische Schwerpunktpraxis, Frauengasse 4 (Villa Gisela), zip code A-4820 Bad Ischl, Austria; telephone 011-(43)-61-32 22511 or alternatively 011-(43)-61-32 23244; teleFAX 011-(43)-61-32 232443. He often speaks English through an interpreter, Hubert Laaber; telephone to Herr Laaber at 011(43) 6132 24568. The elegant monograph written by Dr. med. Rudolf Pekar, Percutaneous Bio-Electrotherapy of Cancerous Tumours, may be acquired from its editor, Gerhard Grois at Wilhelm Maudrich KG, medical publishers, A-1096 Wien, Spitalgasse 21a, Vienna, Austria; telephone 011-(43)-1 408 58 91; teleFAX 011-(43)-1 4085080; or by ordering it directly over the internet at the publisher's website: www.maudrich.com. The price is US$54 per copy. Reference (1.) Pekar, R. Percutaneous Bio-Electrotherapy of Cancerous Tumours: A Documentation of Basic Principles and Experiences with Bio-Electrotherapy. (Wien, Munchen, Bern: Verlag Wilhelm Maudrich, 1997). Table 1 Cancer Reduction Efficiency of Bio-Electrotherapy as Experienced Results from Applying Galvanotherapy to Chinese Cancer Patients
Cancer type Number(#) # % # % # % Total 2516 885 35.2 1080 42.9 379 15.1
Cancertype # % # % Total 172 6.8 1969 78.3 Key: CR is Complete Remission NC is No Change PR is Partial Remission PD is Partial Deterioration
Inventors:Schonfeld, Andreas (Kartaruhe, DE, US) 1. An apparatus for the treatment of tumors (1), comprising at least one generator (5) having at least one power source (2, 2', 3, 3', 4, 4'), and at least two electrode needles (6, 6', 7, 7' 8, 8') by means of which current can be conducted into, or, respectively, out of the tumor (1), and a control means connected to said at least one power source (2, 2', 3, 3', 4, 4') for limiting the respective current flowing through each electrode (6, 6', 7, 7' 8, 8'). 2. An apparatus according to claim 1, wherein a separate power source (2, 2', 3, 3', 4, 4') is provided for each electrode (6, 6', 7, 7' 8, 8'). 3. An apparatus according to claim 1, wherein said power sources (2, 2', 3, 3', 4, 4') are constant current power sources. 4. An apparatus according to claim 1, wherein the current emitted by the power sources (2, 2', 3, 3', 4, 4') is adjustable at least at those power sources (2, 3, 4) by means of which current can be conducted into the tumor (1). Description: [0001] This is is a Continuation-In-Part application of international application PCT/DE03/01178 filed Mar. 30, 2002 and claiming the priority of German application 201 09 099.6 filed May 30, 2001. BACKGROUND OF THE INVENTION [0002] The invention relates to an apparatus for the treatment of tumors, the apparatus comprising at least one generator having a power source, and at least two needle electrodes by means of which current can be conducted into, and out of, the tumor. [0003] Such an apparatus is for instance known from the document "Percutaneous Bio-electrotherapy of Cancerous Tumors", Dr. Med. Rudolf Pekar, Publishing House Wilhelm Maudrich, Vienna-Munich-Berne, 1997. The apparatus disclosed therein comprises two needle-shaped electrodes, one for conducting current into the tumor and one for conducting current out of the tumor. By means of the apparatus known, direct current is conducted through a tumor. This is done by inserting the two needle-shaped electrodes into the tumor, and then applying a DC voltage to the electrodes, so that a direct current flows through the tumor. Such a current is intended to destroy cancerous cells in the tumor. [0004] It has been found that the method is more efficient the more current is conducted through the tumor. Therefore a current is selected which is as high as possible. Since, however, it has also been found that the tissue around the insertion location of the needle-shaped electrode is undesirably damaged by a current of approximately 80 milliampere and more, the current cannot be increased arbitrarily with an apparatus having needle-shaped electrodes. [0005] The apparatus known from the document mentioned comprises two systems with separate outputs. It would thus be conceivable to use both systems in a parallel treatment of one and the same tumor. The current conducted into the tumor might then actually be doubled, with the current conducted into the tumor by each of the electrodes being limited to a maximum value. Since, however, the current travels through the tumor in an uncontrolled manner, it is not guaranteed that the current will, in correspondence with its introduction, again be conducted out of the tumor via the respective pertinent electrode. There is rather the risk that, due to the inhomogenous electric conductivity of the tumor, the current will pass through the tumor in such a way that it predominantly exits via one electrode, and that merely a residual current is conducted out of the tumor via the other electrode. This would destroy the tissue around the needle-shaped electrode via which the major part of the current exits from the tumor. The document therefore does not indicate, either that the two systems may be used in parallel for the treatment of one tumor, but rather it is indicated that the two systems are provided for the treatment of two patients that is of two different tumors at a time. [0006] It the principal an object of the invention to provide an apparatus for the treatment of tumors such that it is suited for the unproblematic treatment of tumors with relatively high currents. SUMMARY OF THE INVENTION [0007] In apparatus for the treatment of tumors, comprising at least one generator having a power source, and at least two electrode needles for conducting current into, or out of, a tumor, a control arrangement is provided for limiting the current flowing through each electrode to a maximum value. [0008] The fact that a control means is available by means of which the respective current flowing through the electrodes can be limited to a maximum value advantageously provides that, at no electrode, more current is conducted into the tumor or, respectively, out of the tumor than is possible without causing damage to the tissue. Due to the control means, several electrodes may be used simultaneously. [0009] Since the maximum current flowing through the electrodes is limited to a maximum value, it remains without consequences, if for instance an electrode is inserted into the tumor at a position that would, due to a high electric conductivity, be chosen as a preferred way out of the tumor by several current paths through the tumor, that is for currents emanating from different electrodes. By the limitation of the current flowing through any of the electrodes to a maximum value, the currents are forced to search for ways through the tumor to other electrodes. [0010] A particular embodiment of the invention has turned out to be particularly advantageous, wherein each electrode is fed by a separate power source. This means that each electrode by means of which current is conducted into the tumor is connected to a separate power source. Likewise, each electrode, by means of which current is conducted out of the tumor, is connected to a power source or, in other words, to a current sink, with the direction of the current being reversed with respect to the power sources. By feeding the electrodes using different power sources and current sinks, respectively, the limitation of the current flowing through the electrodes to a maximum value can be put into practice in a simple manner. [0011] It is of particular advantage when the power sources are designed as constant current power sources. [0012] In another embodiment of the invention, the current supplied by the power sources is adjustable at least for those power sources by which current can be conducted into the tumor. Thus, it is possible in a simple manner to provide for current flows through the tumor, which are locally different. The current flow through the tumor may further be influenced by the fact that the currents taken up by the current sinks can also be adjusted. Irrespective of the adjustability of the currents emitted by the power source or the currents taken up by the current sinks, respectively, the currents to remain limited to a respective maximum value, this maximum value being the same for all power sources or current sinks, respectively. [0013] Further details, features and advantages of the present invention will become more readily apparent from the following description of a particular embodiment with reference to the accompanying drawing: BRIEF DESCRIPTION OF THE DRAWINGS [0014] The sole FIGURE shows an embodiment of an apparatus according to the invention. DESCRIPTION OF A PREFERRED EMBODIMENT [0015] As shown in the FIGURE, a generator 5 comprises several power sources 2, 3, 4 and several corresponding current sinks 2', 3', 4'; the outputs of the power sources 2, 3, 4 are connected to electrode needles 6, 7, 8. The connectors of the current sinks 2', 3', 4' are connected to electrodes needles 6', 7', 8'. The electrode needles 6, 6', 7, 7' 8, 8' are inserted into the tissue of a tumor 1. [0016] The power sources 2, 3, 4 each comprise a control input 2a, 3a, 4a by means of which the maximum value of the current supplied by the respective power source can be adjusted. Furthermore, the power sources 2, 3, 4 each comprises a further control input 2b, 3b, 4b by means of which the current provided by the respective power source can be controlled. The current sinks 2', 3', 4' comprise, similar to the power sources 2, 3, 4, a control input 2'a, 3'a, 4'a by means of which the maximum value of the respective current taken up by the current sinks can be controlled. [0017] If the power sources 2, 3, 4 are adjusted such that they each provide a current of, for instance, 80 milliampere, and if the current sinks 2', 3', 4' are adjusted such that the current maximally taken up by each of them is, for instance, limited to 80 milliamperes, the tumor 1 can be treated with 240 milliampere without the risk of the tissue being damaged at the position of insertion of an electrode. Even if, for instance, the electric conductivity of the tumor 1 were such that a part of the current which is conducted into the tumor 1 by means of the electrode 7 would flow to the electrode 6', and the current conducted into the tumor 1 by the electrode 6 would completely flow to the electrode 6', the limitation of the maximum current of the current sink 2' to 80 milliampere would prevent that the corresponding part of the current conducted into the tumor 1 by means of the electrode 7 will be conducted out of the tumor 1 via the electrode 6'. The current will therefore have to find a way to another electrode, that is, to the electrode 7'. [0018] The invention is of course not limited to the arrangement as shown in the FIGURE. Although the FIGURE only illustrates three power sources and three current sinks, a much higher number of power sources and current sinks can be used. This is indicated by the dotted lines 17 shown in the FIGURE. More on Over several decades, a German and an Austrian physician, Dr. Pekar and Dr. Rilling, have separately developed methods of erasing malignant growths based on the use of electricity. One of Dr. Pekar's (who is now 93) basic premises: "Health and sickness are related to the bio-electric currents in our body". I learned about these doctors on TV, where I remember them specifically citing melanoma, prostate and breast cancer as having been healed by their approaches (see below for more specifics). Dr. Pekar's method in a nutshell: wires are applied directly to the tumor, a few milliamperes are applied for up to 90 minutes; taking melanoma as an example, the cancerous growth will turn into a crust in the space of several weeks (with the crust then being shed by the body). The electric current seals the blood vessels so no metastases are formed (while during operations, the veins are cut which allows cancer cells to swarm). Dr. Pekar posits that cancer is primarily a blood disease and can be detected early via the blood. When asked why his method wasn't more commonly applied, Dr. Pekar replied (his exact words), "Medizin ist ein Geschäft [Medicine is about making money/Medicine is where a lot of money is and can be made]. And with the method I have developed, there isn't much money to be made." He added, "doctors studied so many things at school that my method appears too simple to them." Dr. Siegfried Rilling, MD, has developed a method he calls Biotonometrie based on the electric quality of the human body. The following articles while furnishing scientific details will also give
an excellent general introduction to the subject: Types of Tumors Responding to Galvanotherapy Electrochemical Tumor Therapy (ECT) for Malignancies Bio-Electric Therapy (BET) For the Elimination of Malignant Tumors Prof. Dr. Yu-Ling Xin’s treatment statistics concerning ECT (Electro
Chemo Therapy) Types of Tumors Responding to Galvanotherapy Particular tumor types respond well to galvanotherapy. Under the ministrations of Dr. med. Rudolf Pekar and his oncological colleagues, this form of electrotherapy is successful for eliminating the following malignant conditions: Breast cancers a. The organ involved is preserved with no problematic scarring. From receiving galvanotherapy, certain types of cancer patients benefit greatly. Such malignancy types include: those with small primary tumors of less than 5 cm in diameter; Electrochemical Tumor Therapy (ECT) for Malignancies Healing with electric currents After introduction of this treatment to China by Dr. Bjorn Nordenstroem, this effective and surprisingly low-cost therapy has been used in 108 Chinese hospitals. Countries such as Japan, USA, Italy, Slovenia and Denmark have shown a research interest in this new treatment modality. In Germany there is a private clinic in Bad Aibling and the University Hospital in Witten-Herdecke which use ECT treatment. Too low-cost? Oncology is one of the most expensive and most profitable fields of medicine. Next to Dr. Nordenstroem and Prof. Yu Ling Xin from Peking we must mention Dr. Rudolf Pekar from Bad Ischl in Austria who developed percutaneous electrotherapy after many years of research and practical application. He documented his findings in a book published by Verlag Wilhelm Maudrich* which will serve as the basic source of this article. His theory is based upon the fact that each cell carries a specific electromagnetic field giving rise to bioelectric currents and frequencies in all biological materials. Pekar found that every tumor has an altered electric field which extends beyond the tumor’s borders and which is polarised toward the surrounding tissue. (This field does not automatically disappear after surgical removal of the tumor, a fact which can be measured and proved and which explains the high rate of recurrencies after surgery). We may conclude that an influence exerted upon this field should also affect and modify the tumor. Healing with electric currents In order to understand the mechanism of cancer cells and the fact that they are "masked" from the immune system, one has to look deeper into the functioning of bioelectric currents. An electric voltage is part of all functions in living tissue. It arises primarily at the cellular walls and gives rise to electric currents. That much has been known for a long time in medicine. Movement of electrons along a DC field is being used in e.g. iontophoresis and electrophoresis. Cell membranes contain ion channels. They carry a negative charge at the outside of the cell membrane and show selectivity for kations, particularly for sodium and potassium ions. Part of these ion channels open only after adequate change of the membrane potential. Cell life depends on the nutritional input and adequate excretion of metabolic end products. Both pathways use the ion channels. This metabolism constitutes the flow of electric current. If a cell does not function normally, it emits an electromagnetic field which differs from the healthy field condition. Cancer cells carry a negative membrane potential which is proportional to the degree of their malignancy. This change in potential enables the cell to separate from other cells and to maintain its masking capabilities towards the reconnaissance function of the immune system. The cell's altered protein metabolism produces a membrane attacking enzyme which enables it to penetrate and to infiltrate normal surrounding tissue (Pekar). Cell resonance changes and the dynamic condition of tissue is being destroyed through polarity change. As a result we see a decrease in the electric blockage of cancer-inducing information. It is exactly at this point where the new therapy becomes active. An adjustable DC current is introduced directly into the tumor with the help of electrodes. This triggers the following reactions: Depolarisation and penetration of tumor cell membranes leading to a disturbance of metabolic function and intercellular structure. The energetic ionic flow of current is re-established at the same time in accordance with the naturally intended structure of the organism. This represents an iatrogenic stimulation of self-healing and an activation of the immune system. Pekar also maintains that 'every tumor is registered in the central nervous system and that this CNS representation can be treated with electric currents.' [Compare Dr. Hamer’s New Medicine.] Sending electric currents through tumour tissue leads to electrolytic changes at the electrodes which in turn causes significant alterations of the pH value. As that pH value differs from the normal physiological range it will be destructive for tumor tissue. The results show an aseptic necrosis of tissue and an accompanying "unmasking" of the cancer cells now made recognizable to the immune system. The phagocytic cells (stimulated where required via additional immunotherapy) will break down and destroy the dead remnants of the tumor within one to three weeks. So far, there have been no side effects associated with this treatment and there is no reason to expect them. (The degree of malignancy plays no part). A great deal of expertise is required for proper placement of electrodes and optimal adjustment of current intensity which must be set in accordance with the size, density and type of tumor being treated. Rudolf Pekar and others have published suggestions for appropriate treatment modalities based on their experience. A therapeutic device for this purpose is available. A single treatment session lasts 10 to 90 minutes, can be performed as an outpatient procedure, and does usually not produce any pain or inflammation. The patient can leave the doctor's office right after treatment. This therapy is suitable both for superficial and deeper tumors, such as breast cancer, ENT tumors, all types of skin cancer, isolated metastasis of internal organs, soft tissue tumors, lymph node. Tumours pretreated radiologically or with chemotherapy as well as metastases within lymphatic areas spreading throughout the body and bone metastases (osteometastasis) can be treated to a limited extent. A case history *Pekar, Rudolf: ”Die perkutane Bio-Elektrotherapie bei Tumoren.
Eine Dokumentation zu Grundlage und Praxis der perkutanen Galvanotherapie”. Contact addresses: Dr. med. Rudolf Pekar, Frauengasse 4, A-4820 Bad Ischl, Austria
Bio-Electric therapy has been used clinically for many years. It has been applied in orthopedics, where it has been used for regeneration and healing of broken bones as well as in the treatment of pain. In oncology ... the use of BioElectric Therapy (BET) is ... the result of research investigations by Dr. Rudolf Pekar and Björn Nordenström. Electrodes are attached to acupuncture needles that are inserted directly into the tumor or into the skin surrounding the tumor. Applying the correct level of voltage (usually only 9.5 to 10 volts) and low micro-amperage results in the destruction of cancerous cells. ...As soon as direct current is connected to the electrodes, different electrochemical reactions influence the pH value and can cause electrolysis of tumor tissue. Depolarization of the cell membrane changes the cellular environment, forcing the tumor cells to be gently destroyed. The consequence of this process is the interruption of certain functions within the cancerous cells, which, in turn, can lead to the destruction of these cells. The application of direct current causes tumor cells to lose their immune disguise and be transformed, within minutes, into an allergen. The tumor then becomes recognizable by the immune system, which then activates the proper defense cascade, including cytokines and interferon and most importantly, the cytotoxic T-cells. What Types of Tumors are Suitable for BET? Small mamma carcinomas or isolated axillary supraclavicular and In this way, cytostatics can be introduced into the tumorous tissue in a very targeted and concentrated manner. This method can be more effective on the tumor site than standard systemic chemotherapy or local cytostatic perfusion. Cytostatic substances are best applied to hollow organs - for example, esophagus, bladder, stomach and rectum. The membrane potentials are changed so much by the current that the cells open and absorb cytostatic substance more rapidly. ...During the treatment, the patient will experience a slight pressure pain or a slight tingling in the treated area. Direct current brings about long lasting pain relief because it inhibits the activity of sensory nerve fibers. Therefore, there is no pain after treatment. At the Second International Conference of Bio-Electrotherapy for Cancer held in Stockholm, Sweden, in 1993, the Chinese oncological participants reported that their administration of BET to 4,000 cancer patients resulted in an accumulation of Complete Remissions and Partial Remissions (CR+PR) exceeding 80%. BioElectric Therapy is safe and effective, does not require any hospitalization,
complements other therapies, and has a low price tag when compared to surgical
intervention. Prof. Dr. Yu-Ling Xin’s treatment statistics concerning ECT (Electro Chemo Therapy) Prof. Xin, Peking, has written a "treatment statistics concerning
ECT (Electro Chemo Therapy) in 9011 cases of different types of tumor" compiled
from 168 clinics. More articles by him et al. can be found on the Internet. According to one German source (a naturopathic institute applying Electro Cancer Therapy), this treatment modality is recommended and endorsed by the National Cancer Control Society L.A. and the American Academy of Preventive Medicine Cap. Can. Fl. (among other associations). Addendum by Healing Cancer Naturally © 2004 Eminent cancer treatment researcher Lothar Hirneise, author of “Chemotherapy
Heals Cancer and the World is Flat”, gives the following ‘Personal
opinion’ in his chapter on Galvanotherapy: “Galvano-therapies
are certainly an interesting approach for tumor destruction. this is why
an increasing number of physicians and homeopathic practitioners are using
this therapy in Germany. For me it was very interesting to note that 20
years ago Dr. Pekar still advised his patients to have operations, and
in summarizing his more than 50 years of work as an oncologist, he said
that today in most cases he would no longer advise an operation, because
he frequently could see that particularly women with breast cancer lived
much longer if they did not have surgery. (Now other therapists also represent
this opinion.) |